1. Home
  2. GNPX vs FBGL Comparison

GNPX vs FBGL Comparison

Compare GNPX & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • FBGL
  • Stock Information
  • Founded
  • GNPX 2009
  • FBGL 1996
  • Country
  • GNPX United States
  • FBGL Singapore
  • Employees
  • GNPX N/A
  • FBGL N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • FBGL Miscellaneous manufacturing industries
  • Sector
  • GNPX Health Care
  • FBGL Consumer Discretionary
  • Exchange
  • GNPX Nasdaq
  • FBGL Nasdaq
  • Market Cap
  • GNPX 7.4M
  • FBGL 8.5M
  • IPO Year
  • GNPX 2018
  • FBGL 2025
  • Fundamental
  • Price
  • GNPX $0.17
  • FBGL $0.52
  • Analyst Decision
  • GNPX
  • FBGL
  • Analyst Count
  • GNPX 0
  • FBGL 0
  • Target Price
  • GNPX N/A
  • FBGL N/A
  • AVG Volume (30 Days)
  • GNPX 6.3M
  • FBGL 38.7K
  • Earning Date
  • GNPX 08-14-2025
  • FBGL 01-01-0001
  • Dividend Yield
  • GNPX N/A
  • FBGL N/A
  • EPS Growth
  • GNPX N/A
  • FBGL N/A
  • EPS
  • GNPX N/A
  • FBGL N/A
  • Revenue
  • GNPX N/A
  • FBGL $10,146,582.00
  • Revenue This Year
  • GNPX N/A
  • FBGL N/A
  • Revenue Next Year
  • GNPX N/A
  • FBGL N/A
  • P/E Ratio
  • GNPX N/A
  • FBGL N/A
  • Revenue Growth
  • GNPX N/A
  • FBGL N/A
  • 52 Week Low
  • GNPX $0.14
  • FBGL $0.44
  • 52 Week High
  • GNPX $3.97
  • FBGL $5.45
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 35.07
  • FBGL N/A
  • Support Level
  • GNPX $0.14
  • FBGL N/A
  • Resistance Level
  • GNPX $0.25
  • FBGL N/A
  • Average True Range (ATR)
  • GNPX 0.02
  • FBGL 0.00
  • MACD
  • GNPX -0.01
  • FBGL 0.00
  • Stochastic Oscillator
  • GNPX 23.78
  • FBGL 0.00

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

Share on Social Networks: